Which is better, moboxetinib or suvotinib?

Mobocertinib/Mobocertinib and Suvotinib are both drugs used to treat lung cancer, but which drug is better depends on the patient's specific situation and the doctor's advice. The specific treatment plan should be decided by the doctor based on the patient's specific situation.

Mobosetinib is a kinase inhibitor that targets EGFR exon 20 insertion mutations. It is suitable for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who carry EGFR exon 20 insertion mutations and have progressed after treatment with first- or second-generation targeted drugs. Savolitinib is a potent, orally active, precision inhibitor of FGFR fusion and mutant tumors, based on the treatment of patients with non-small cell lung cancer/pulmonary sarcomatoid cancer. Suvotinib was recently approved in China (conditional on results from a Phase III trial) for the treatment of metastatic non-small cell lung cancer with MET exon 14 skipping alterations in patients who have progressed after or are intolerant to platinum-based chemotherapy, based on results from a pivotal Phase II trial. Suvotinib may be an optional treatment option if a patient develops resistance to mobosetinib.

Mobosetinib The original drug is currently on the market in China and has not yet been included in the medical insurance. SpecificationThe price of 40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specifications40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory40mg*120 pills per boxThe pricemay be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.